Research summary
Retatrutide has been evaluated in published phase 2 clinical trials in adults with obesity and with type 2 diabetes, with reports of changes in body weight, glycaemic markers and gastrointestinal adverse events. Later-phase trials are ongoing and it is not an approved medicine. This summary describes what the literature has investigated. It is not a claim about the effects of our product, which is supplied for laboratory research only.
Mechanism of action
Retatrutide (LY3437943) is a synthetic peptide agonist that acts on three receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon receptor. These receptors are involved in appetite regulation, insulin secretion and hepatic and energy metabolism.
Chemical properties
Class: synthetic fatty-acid-modified peptide, triple GIP/GLP-1/glucagon receptor agonist. Form: pre-filled pen. Exact sequence, molecular weight, purity, identity and content: see the batch Certificate of Analysis.
Storage and handling
Supplied as a pre-filled pen. Store as stated on the product label and Certificate of Analysis, typically cold and protected from light. Avoid freezing and repeated temperature cycling unless the label states otherwise. For laboratory research use only.
Literature references
Selected PubMed records on retatrutide, scientific background only, not claims about our product. PMID 40563436: retatrutide in obesity pharmacotherapy (review). PMID 37366315: triple-hormone-receptor agonist for obesity, phase 2 trial. PMID 42250575: efficacy and safety of retatrutide, a GIP, GLP-1 and glucagon receptor agonist, in people with type 2 diabetes. Open any record at https://pubmed.ncbi.nlm.nih.gov/PMID/ . More: https://pubmed.ncbi.nlm.nih.gov/?term=retatrutide
For laboratory research use only. Not for human or veterinary use. Nothing on this page is medical advice.
